Objective classification of multiple sclerosis disease course results in frequent reclassification to secondary progressive multiple sclerosisKarolinska Inst, Stockholm, Sweden..
Karolinska Inst, Stockholm, Sweden..
Czech Natl Multiple Sclerosis Patient Registry, IMPULS Endowment Fund, Prague, Czech Republic..
Charles Univ Prague, Fac Med 1, Prague, Czech Republic..
Gen Univ Hosp, Dept Neurol, Prague, Czech Republic.;Gen Univ Hosp, Ctr Clin Neurosci, Prague, Czech Republic..
Gen Univ Hosp, Dept Neurol, Prague, Czech Republic.;Gen Univ Hosp, Ctr Clin Neurosci, Prague, Czech Republic.;Rigshospitalet, Dept Neurol, Danish Multiple Sclerosis Registry, Copenhagen, Denmark..
MS Forschungs & Projektentwicklungs gGmbH, Hannover, Germany..
MS Forschungs & Projektentwicklungs gGmbH, Hannover, Germany..
Melbourne Hlth, Melbourne, FL USA..
Swansea Univ, Sch Med, Swansea, W Glam, Wales..
Swansea Univ, Sch Med, Swansea, W Glam, Wales..
Swansea Univ, Sch Med, Swansea, W Glam, Wales..
Imperial Coll London, Dept Cellular & Mol Neurosci, London, England.;UCL Inst Ophthalmol, Dept Visual Neurosci, London, England..
Novartis Pharma AG, Basel, Switzerland..
Novartis Pharma AG, Basel, Switzerland..
Novartis Pharma AG, Basel, Switzerland..
Novartis Pharma AG, Basel, Switzerland..
Karolinska Inst, Stockholm, Sweden..
Show others and affiliations
2021 (English)In: Neurology, ISSN 0028-3878, E-ISSN 1526-632X, Vol. 96, no 15Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
LIPPINCOTT WILLIAMS & WILKINS , 2021. Vol. 96, no 15
National Category
Neurosciences
Identifiers
URN: urn:nbn:se:kth:diva-306987ISI: 000729283603324OAI: oai:DiVA.org:kth-306987DiVA, id: diva2:1630428
Note
QC 20220120
2022-01-202022-01-202022-06-25Bibliographically approved